secwatch.observer — SEC 8-K summary
======================================

Issuer:     NGM BIOPHARMACEUTICALS INC (—)
CIK:        0001426332
Form:       8-K
Filed at:   2024-04-05T23:59:59+00:00
Accession:  0001193125-24-088076
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NGM Bio completes $1.55/share acquisition by Column Group affiliate, goes private
--------------------------------------------------------------------------------

- Tender offer closed April 4, 2024; 22,323,295 shares (27% of outstanding) validly tendered at $1.55 each.
- Additional 39,516,567 shares contributed by TCG affiliates under rollover agreements for Parent shares.
- Merger completed April 5, 2024; NGM Bio becomes wholly-owned private subsidiary of Parent.
- Common stock delisted from Nasdaq prior to April 5 trading; deregistration to follow.
- Three independent directors resigned as of Effective Time; CEO David Woodhouse remains as director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426332/000119312524088076/0001193125-24-088076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426332/000119312524088076/d813269d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-088076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer